Volume 3 Issue 4, April 2019

Volume 3 Issue 4

Urinary nanosensors of allograft rejection

This issue highlights nanosensors for the non-invasive early detection of acute transplant rejection, an immunotoxin that suppresses autoimmunity, the enhancement of T-cell antitumour responses via the inhibition of PD-L1 palmitoylation, enhanced antitumour activity by a nanomedicine encapsulating a docetaxel prodrug and conjugated to an ephrin-receptor-specific antibody, and the combination of high-throughput nanoparticle synthesis and machine learning to efficiently explore structure–activity relationships for nanomedicines.

The cover illustrates nanoparticle sensors of the activity of the protease granzyme B, for the detection of acute rejection of transplanted skin grafts.

See Mac et al.

Image: Ella Maru Studio. Cover Design: Alex Wing.

Editorial

News & Views

  • News & Views |

    An antibody-modified nanoparticle encapsulating a pH-sensitive taxane prodrug, and targeting an overexpressed receptor in tumours, improves the tolerability and anticancer efficacy of the active drug in multiple animal models.

    • Ernesto Moles
    •  & Maria Kavallaris
  • News & Views |

    Nanoparticle sensors of the activity of the protease granzyme B detect early T-cell-mediated rejection of transplanted skin grafts in mice via the release of a proteolytically cleaved fluorescence reporter that filters into urine.

    • Anita S. Chong
  • News & Views |

    Depletion of cells expressing the cell-membrane protein programmed cell-death protein-1 using an antibody-based toxin delays the onset of disease in a mouse model of diabetes and reverses paralysis in mice with experimental autoimmune encephalomyelitis, without compromising physiological immunity.

    • Zhirui Wang
    •  & Christene A. Huang
  • News & Views |

    Enhanced lysosomal degradation of the transmembrane protein programmed cell-death protein-1 ligand in tumour cells, enabled by blocking the protein’s post-translational lipid modification, promotes T-cell-mediated suppression of tumour growth in mice.

    • Stephane Lefrancois
  • News & Views |

    High-throughput nanoparticle synthesis combined with machine learning speeds up the exploration of structure–activity relationships for nanomedicines, as shown for spherical nucleic acids functioning as cancer-vaccine candidates.

    • Yijing Liu
    •  & Xiaoyuan Chen

Comment & Opinion

Research

  • Article |

    A nanomedicine encapsulating a docetaxel prodrug, and conjugated to an antibody specific for the receptor EphA2, provides enhanced antitumour activity in multiple tumour-xenografted mice, and has minimal toxicity in rats and dogs.

    • Walid S. Kamoun
    • , Dmitri B. Kirpotin
    • , Zhaohua Richard Huang
    • , Suresh K. Tipparaju
    • , Charles O. Noble
    • , Mark E. Hayes
    • , Lia Luus
    • , Alexander Koshkaryev
    • , Jaeyeon Kim
    • , Ken Olivier
    • , Tad Kornaga
    • , Shinji Oyama
    • , Vasileios Askoxylakis
    • , Christine Pien
    • , Geoffrey Kuesters
    • , Nancy Dumont
    • , Alexey A. Lugovskoy
    • , Sarah A. Schihl
    • , John H. Wilton
    • , Melissa L. Geddie
    • , James Suchy
    • , Stephanie Grabow
    • , Neeraj Kohli
    • , C. Patrick Reynolds
    • , Rachel Blaydes
    • , Yu Zhou
    • , Andrew J. Sawyer
    • , James D. Marks
    •  & Daryl C. Drummond
  • Article |

    Nanosensors of the activity of the protease granzyme B, which release a cleaved fluorescence reporter that filters into urine, enable the early diagnosis of acute transplant rejection in mice.

    • Quoc D. Mac
    • , Dave V. Mathews
    • , Justin A. Kahla
    • , Claire M. Stoffers
    • , Olivia M. Delmas
    • , Brandon Alexander Holt
    • , Andrew B. Adams
    •  & Gabriel A. Kwong
  • Article |

    An immunotoxin incorporating an anti-programmed-cell-death-protein-1 (PD-1) single-chain variable fragment selectively eliminates PD-1-expressing cells, and suppresses autoimmunity while preserving adaptive immunity in mouse models of autoimmune disease.

    • Peng Zhao
    • , Peng Wang
    • , Shuyun Dong
    • , Zemin Zhou
    • , Yanguang Cao
    • , Hideo Yagita
    • , Xiao He
    • , Song Guo Zheng
    • , Simon J. Fisher
    • , Robert S. Fujinami
    •  & Mingnan Chen
  • Article |

    The physiological degradation of programmed-death ligand 1 is reduced by the palmitoylation of its intracellular domain, and this process can be inhibited to promote T-cell immunity against tumours.

    • Han Yao
    • , Jiang Lan
    • , Chushu Li
    • , Hubing Shi
    • , Jean-Philippe Brosseau
    • , Huanbin Wang
    • , Haojie Lu
    • , Caiyun Fang
    • , Yao Zhang
    • , Lunxi Liang
    • , Xiaolin Zhou
    • , Chaojun Wang
    • , Yu Xue
    • , Yun Cui
    •  & Jie Xu

Amendments & Corrections